Previous 10 | Next 10 |
The genetics industry supports every other life science industry, with one contribution being the discovery of new genetic drivers of diseases. In terms of the genetic testing market, this area has grown substantially over the last few years thanks to advances made in technology ; in lin...
Arcturus Therapeutics (NASDAQ: ARCT ): Q3 GAAP EPS of -$0.56 misses by $0.09 . More news on: Arcturus Therapeutics Holdings Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today reported it...
SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (NASDAQ: ARCT, the “Company”), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that the Company is expand...
SAN DIEGO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it will provide a corporate overview and financial...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stoc...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Gainers: PDS Biotechnology (NASDAQ: PDSB ) +23% . The Meet Group (NASDAQ: MEET ) +20% . Synthesis Energy Systems (NASDAQ: SES ) +14% . Microbot Medical (NASDAQ: MBOT ) +19% . TuanChe (NASDAQ: TC ) +14% . Arcturus Therapeutics Holdings (NASDAQ: ARCT ) +14% . Sorrento Therapeutics (NA...
SAN DIEGO, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced t...
Arcturus Therapeutics (NASDAQ: ARCT ) has entered into definitive agreements with certain institutional investors for the purchase and sale in a registered direct offering of 850,000 common shares at $11.50/share, for gross proceeds of ~$9.8M. More news on: Arcturus Therapeutics Holdings...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...